Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Rev Respir Med. 2011 Dec;5(6):747-56. doi: 10.1586/ers.11.73.

Omalizumab in the treatment of asthma.

Author information

1
California Allergy and Asthma Medical Group Inc., 11645 Wilshire Boulevard, Suite 1155, Los Angeles, CA 90025, USA.

Abstract

Omalizumab was introduced in 2003 and is the first asthma drug to target IgE, the allergic antibody that initiates the allergic cascade. Well-controlled studies and post-marketing clinical experience have shown it to be an effective and safe medication. Treatment guidelines now recommend omalizumab as an add-on option for patients with moderate-to-severe allergic asthma uncontrolled on high-dose inhaled corticosteroids and long-acting β-agonists. Despite initial concerns, there is no evidence of any association with malignancy at this time. In our opinion, omalizumab is well-tolerated and significantly improves pulmonary function, decreases clinical symptoms and improves the quality of life in patients with uncontrolled allergic asthma.

PMID:
22082161
DOI:
10.1586/ers.11.73
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center